Estudo randomizado | Lopinavir-ritonavir e hidroxicloroquina pioraram os desfechos em pacientes criticamente doentes com COVID-19.

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial – Intensive Care Medicine

Comentário no Twitter (fio – clique para saber mais)

Results of @remap_cap #Covid_19 #Antiviral Domain released Online First @yourICM: Among critically ill patients with COVID-19, #lopinavir-ritonavir, #HydroxyChloroquine, or combination therapy worsened outcomes compared to no antiviral therapy

— remap-cap (@remap_cap) July 13, 2021